Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02106988 · ClinicalTrials.gov registry record · Phase 2
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
A Phase 2 study of Lymphoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02106988: Recruiting Phase 2 study of Lymphoma, sponsored by M.D. Anderson Cancer Center.
NCT02106988 is a Phase 2 study of Lymphoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02106988, a Phase 2 study of Lymphoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied. This is an investigational study. Radiation and chemotherapy are FDA approved and commercially available for patients with Stage 1 and/or 2 NK cell lymphoma. The combination of these therapies given at the same time is investigational. Up to 40 patients will take part in this study. All will be enrolled at MD Anderson.
Primary Outcome
Progression defined as progressive disease or death due to disease. The evaluation of PFS will include all participants who receive radiation, regardless of whether they receive chemotherapy. Progression free survival measured from protocol entry.
Conditions Studied
Interventions
- DRUG Mesna
- RADIATION Radiation Therapy
- DRUG Dexamethasone
- DRUG Ifosfamide
- DRUG Etoposide phosphate
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-01-16 |
| Est. Completion | 2034-01-31 |
| Phase | Phase 2 |
What NCT02106988 shows while recruiting
NCT02106988 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Mesna is the first listed.
NCT02106988 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02106988 about?
NCT02106988 is a clinical study titled "Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma". The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied. This is an investigational study. Radiation and chemotherapy are FDA approved...
What is the current status of trial NCT02106988?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2015-01-16. Estimated completion is 2034-01-31.
What conditions does trial NCT02106988 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT02106988?
The interventions under investigation include: Mesna (DRUG), Radiation Therapy (RADIATION), Dexamethasone (DRUG), Ifosfamide (DRUG), Etoposide phosphate (DRUG).
Who is sponsoring clinical trial NCT02106988?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02106988 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02106988's enrollment target sits among peer trials
40 174th of 299 higher than 116 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
- NCT02254863 · 40 participants · Phase 1
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI